SCHEMBL22657669

SCHEMBL22657669

OCCc1ccc2c(c1)OC(F)(F)O2

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 3/20 0.43
WNT3A P56704 3/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX5 P09917 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
BACE1 P56817 1/20 0.42
PTGS2 P35354 8/20 0.42
CYP19A1 P11511 1/20 0.41
FAAH O00519 2/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
CA2 P00918 1/20 0.38
SLC6A4 P31645 1/20 0.37
ROCK2 O75116 1/20 0.37
PTGDR Q13258 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL80862 0.89 CTNNB1 (0.41) CTNNB1WNT3APTGS2CYP19A1FAAH
SCHEMBL351795 0.85 CTNNB1 (0.45) CTNNB1WNT3ACYP19A1FAAHMRGPRX4
SCHEMBL25446354 0.83 KDM4E (0.44) KDM4EALDH1A1ALOX5GAAMAPT
SCHEMBL22657573 0.83 CTNNB1 (0.41) CTNNB1WNT3ACYP19A1FAAHMRGPRX4
SCHEMBL31490194 0.81 ALOX15 (0.53) KDM4EALDH1A1ALOX5GAAMAPT
SCHEMBL367973 0.81 ALOX15 (0.53) KDM4EALDH1A1ALOX5GAAMAPT
SCHEMBL1971747 0.81 TAAR1 (0.53) CTNNB1WNT3AKDM4EALDH1A1GAA
SCHEMBL8367478 0.81 CNR1 (0.40) CTNNB1WNT3ACYP19A1FAAHMRGPRX4
SCHEMBL80920 0.80 FAAH (0.40) CTNNB1WNT3ACYP19A1FAAHMRGPRX4
Hydrochloric Acid SCHEMBL4511238 0.80 TAAR1 (0.51) CTNNB1WNT3AKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 EP disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 CN disclosed
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2022-07-07 US disclosed
EP-3966199-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2022-03-16 EP disclosed
CN-114174263-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2022-03-11 CN disclosed
WO-2020229968-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2020-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA CTNNB1 4849/4885WNT3A 4715/4885KDM4E 2704/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 CTNNB1 4438/4885WNT3A 4137/4885KDM4E 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.